A panel of government health experts says a highly anticipated Eli Lilly blood thinner has lifesaving potential, but should not be given to patients with a history of stroke.
Expert advisers to the Food and Drug Administration say the drug's labeling should alert doctors that stroke patients face a high risk of suffering another stroke if they take the medication.
The panel will vote later today on whether to recommend approval of the experimental drug. The FDA is not required to follow the group's recommendations, though it usually does.
Indianapolis-based Eli Lilly has asked the Food and Drug Administration to approve its highly anticipated drug to prevent dangerous blood clots in patients with acute heart problems.